Crawford 1986.

Study characteristics
Methods	Randomised, 2‐period cross‐over study
Participants	32 people Tumour type: adenocarcinoma of the ovary or germ cell tumours. Chemotherapy regimen: cisplatin 100 mg/m2, cyclophosphamide and doxorubicin (for people with adenocarcinoma of ovary), cisplatin 120 mg/m2, methotrexate and vincristine (for people with germ cell tumours). No information on doses reported Chemotherapy emetogenicity: high
Interventions	Nabilone 1 mg orally every 8 hours, n = 32 Metoclopramide 1 mg/kg IV every 3 hours, n = 32
Outcomes	Episodes of vomiting during 24 hours, nausea, dizziness, euphoria and drowsiness
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not reported
Allocation concealment (selection bias)	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	High risk	7/32 (22%) participants received the 4 planned treatment and only 37/64 (58%) participants received 1 or 2 treatment episodes of nabilone and 39/64 (61%) participants received 1 or 2 treatment episodes of metochlopramide
Selective reporting (reporting bias)	Low risk	Data reported for primary outcome
Other bias	High risk	Assumed washout period sufficient. Paired analysis was not performed. Unclear if groups were balanced at baseline
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Reported as "double‐blind"
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Blinding assumed as study reported as "double‐blind"